NVS

The company is young as a brand but old as an enterprise. Novartis was created in 1996 through the merger of two long-established Swiss firms, Ciba-Geigy and Sandoz, in what was at the time the largest corporate merger ever announced, with a combined value above seventy billion dollars. The constituent businesses trace their chemical and dye-making origins back roughly two and a half centuries in the Basel region, which grew into one of Europe's densest clusters of pharmaceutical and specialty-chemical expertise. For most of its early modern history Novartis was a sprawling, diversified life-sciences conglomerate. It owned a large generics business in Sandoz, an eye-care division in Alcon, a consumer health franchise, an animal health unit, and a significant minority stake in the rival Swiss drugmaker Roche. The Novartis of the 2000s and early 2010s looked less like a focused drug company and more like a holding structure spanning many corners of healthcare.

The transformation into a single-purpose medicines company is the defining corporate event of the last decade and the key to understanding the business today. The animal health unit was divested. The consumer health operation was folded into a joint venture with GlaxoSmithKline and then sold back to GSK. Alcon, the eye-care business that Novartis had acquired for more than fifty billion dollars, was spun off to shareholders in 2019 as an independent listed company. Sandoz, the generics and biosimilars arm, was spun off in 2023 and now trades on its own. The large Roche stake was sold back to Roche. The cumulative effect of these moves, executed across more than one hundred billion dollars of transactions, was to strip away everything that was not a patented, research-intensive prescription medicine. An investor looking at NVS today is looking at the residue of that simplification, a company that chose narrowness and higher margins over breadth and diversification.

What Novartis sells now is branded innovative drugs, and the portfolio is built around a handful of large franchises plus a long tail of specialty therapies. Entresto, a treatment for chronic heart failure, has been the single biggest product for years and a major profit contributor. Cosentyx treats psoriasis, psoriatic arthritis, ankylosing spondylitis, and related immune-mediated conditions, and because it is a biologic rather than a small molecule, it is harder for competitors to copy. Kisqali, used in hormone-receptor-positive breast cancer, has been one of the faster-growing products in the portfolio. Leqvio is a twice-yearly injectable that lowers LDL cholesterol using RNA interference, a mechanism Novartis acquired through its purchase of The Medicines Company. The radioligand therapies, principally Pluvicto for prostate cancer and Lutathera for certain neuroendocrine tumors, represent a distinctive bet. These drugs deliver targeted radiation directly to cancer cells and require specialized manufacturing and supply chains that are difficult to replicate, giving Novartis an early lead in a treatment class that few competitors can match at scale.

The economic engine of a company like this is the patent. A branded drug that works and is protected by intellectual property can be sold at a high price with very high gross margins for the life of its exclusivity, because the marginal cost of manufacturing a pill or an injection is small relative to the price. The durable advantage is not a factory or a distribution network, although Novartis has both, but the combination of a deep research pipeline, the regulatory and clinical-trial machinery to move molecules through approval, and the global commercial reach to sell an approved drug into well over a hundred countries quickly. The difficulty is that this advantage is rented, not owned. Every successful drug eventually loses patent protection, at which point generic or biosimilar competition collapses its price and most of its revenue within a year or two. The entire business model is therefore a treadmill. Novartis must continually discover, license, or acquire new medicines fast enough to replace the ones falling off patent. The market rewards companies that win this race with premium valuations and punishes those that fall behind.

That treadmill brings the central near-term risk into sharp focus. Novartis faces what is, by its own description, its largest patent-expiry period around 2026, driven principally by the loss of exclusivity on Entresto, alongside older products such as the cancer drug Tasigna and the blood-disorder treatment Promacta, known as Revolade outside the United States. Entresto in particular faces cheaper generic copies in major markets, and the company has signaled that this cliff will weigh on its results as the lost sales work through the numbers. A patent cliff of this size is the recurring stress test of the pharmaceutical model. The relevant question for an investor is not whether the cliff exists, because it always does, but whether the pipeline and recent launches can grow fast enough to absorb the loss and return the company to growth on the other side.

Competition in innovative medicines comes from a familiar set of large-cap rivals. Novartis competes against the other major branded drugmakers, including Roche, Merck, Pfizer, Bristol Myers Squibb, AstraZeneca, Johnson and Johnson, and Eli Lilly, both in the clinic for the best new molecules and in the market for prescribing share within each disease area. The contest is fought drug by drug and indication by indication rather than across the company as a whole. In radioligand therapy Novartis is closer to a first mover than a follower, having built manufacturing and clinical capability that newer entrants are still assembling. In larger, more crowded categories such as immunology and cardiovascular disease, it is one strong competitor among several, and pricing pressure from payers and governments is a constant feature. The company also competes for assets, bidding against peers and private capital to acquire promising biotech companies before their drugs are proven.

Leadership has been central to the repositioning. Vas Narasimhan, a physician by training, became chief executive officer in 2018 and has been the architect of the strategy to concentrate the company on patented medicines and to lean into newer modalities such as gene therapy, RNA-based drugs, and radioligand therapy. His tenure is associated with the divestitures described above and with a disciplined approach to capital deployment. Giovanni Caforio, the former chief executive of Bristol Myers Squibb, became chair of the board in 2025, bringing additional pharmaceutical operating experience to the top of the governance structure. The management style under Narasimhan has emphasized focus, productivity in research and development, and a steady cadence of bolt-on acquisitions rather than transformational mega-mergers.

The forward strategy follows directly from the structure the company has built. Novartis intends to grow through internal research and through bolt-on acquisitions, typically targets valued below five billion dollars, that add assets in its four priority areas rather than reshaping the company wholesale. It has been an active acquirer, completing dozens of transactions in recent years, including the purchase of Mariana Oncology to deepen the radioligand pipeline and a multibillion-dollar deal for the immunology biotech Excellergy. The strategic logic is to use the high cash generation of the current portfolio to buy and develop the next generation of medicines, concentrating bets where the company already has scientific and commercial strength. Radioligand therapy, where Novartis is advancing programs across multiple cancer indications, is the clearest example of the company trying to own an emerging treatment class rather than chase an established one.

The risks extend beyond the patent cliff. Drug development is inherently uncertain, and expensive late-stage trial failures can erase years of investment with little warning. Pricing is under sustained political pressure in the United States, the company's most profitable market, where legislation that allows the government to negotiate prices on certain drugs introduces a new and growing headwind for the whole industry. As a Swiss company reporting in dollars and selling globally, Novartis carries currency risk that can swing reported results independent of underlying demand. Acquisitions, the core of its growth strategy, can be overpaid or fail to deliver the pipeline value that justified them. Manufacturing complex products such as radioligand therapies and biologics introduces supply and quality risks that simpler pills do not carry. And the simplification that made the company more profitable also made it less diversified, so a stumble in one of the four therapeutic areas now matters more to the whole than it would have in the conglomerate era.

The way to frame Novartis for an investor is as a focused, high-margin bet on the durability of pharmaceutical innovation, stripped of the offsetting ballast that generics, devices, and consumer products once provided. Management has made a clear choice. It traded breadth for focus and accepted higher exposure to patent cliffs in exchange for higher profitability and a cleaner story. That choice is being tested in real time by the Entresto cliff, and the answer will come from the pipeline, from radioligand therapy and immunology and the steady stream of bolt-on deals, rather than from the products that built the company. The open question is not whether Novartis can manage a patent expiry, which it has done repeatedly across its history, but whether a narrower, more concentrated company can keep refilling its pipeline fast enough to make focus pay better than diversification did. The verdict on that trade-off is what an investor in NVS is ultimately underwriting.